OBJECTIVES: The purpose of this study was use molecular imaging targeting coagulation pathway and inflammation to better understand the pathophysiology of silent brain ischemia (SBI) and monitor the effects of factor XIIa inhibition. BACKGROUND: SBI can be observed in patients who undergo invasive vascular procedures. Unlike acute stroke, the diffuse nature of SBI and its less tangible clinical symptoms make this disease difficult to diagnose and treat. METHODS: We induced SBI in mice by intra-arterial injection of fluorescently labeled microbeads or fractionated clot into the carotid artery. After SBI induction, diffusion-weighted magnetic resonance imaging was performed to confirm the presence of microinfarcts in asymptomatic mice. Molecular imaging targeting the downstream factor XIII activity (single-photon emission computed tomography/computed tomography) at 3 h and myeloperoxidase activity (magnetic resonance imaging) on day 3 after SBI induction were performed, without and with the intravenous administration of a recombinant selective factor XIIa inhibitor derived from the hematophagous insect Triatoma infestans (rHA-Infestin-4). Statistical comparisons between 2 groups were evaluated by the Student t test or Mann-Whitney U test. RESULTS: In SBI-induced mice, we found abnormal activation of the coagulation cascade (factor XIII activity) and increased inflammation (myeloperoxidase activity) close to where emboli lodge in the brain. rHA-Infestin-4 administration significantly reduced ischemic damage (53% to 85% reduction of infarct volume, p < 0.05) and pathological coagulation (35% to 39% reduction of factor XIII activity, p < 0.05) without increasing hemorrhagic frequency. Myeloperoxidase activity, when normalized to the infarct volume, did not significantly change with rHA-Infestin-4 treatment, suggesting that this treatment does not further decrease inflammation other than that resulting from the reduction in infarct volume. CONCLUSIONS: Focal intracerebral clotting and inflammatory activity are part of the pathophysiology underlying SBI. Inhibiting factor XIIa with rHA-Infestin-4 may present a safe and effective treatment to decrease the morbidity of SBI.
OBJECTIVES: The purpose of this study was use molecular imaging targeting coagulation pathway and inflammation to better understand the pathophysiology of silent brain ischemia (SBI) and monitor the effects of factor XIIa inhibition. BACKGROUND:SBI can be observed in patients who undergo invasive vascular procedures. Unlike acute stroke, the diffuse nature of SBI and its less tangible clinical symptoms make this disease difficult to diagnose and treat. METHODS: We induced SBI in mice by intra-arterial injection of fluorescently labeled microbeads or fractionated clot into the carotid artery. After SBI induction, diffusion-weighted magnetic resonance imaging was performed to confirm the presence of microinfarcts in asymptomatic mice. Molecular imaging targeting the downstream factor XIII activity (single-photon emission computed tomography/computed tomography) at 3 h and myeloperoxidase activity (magnetic resonance imaging) on day 3 after SBI induction were performed, without and with the intravenous administration of a recombinant selective factor XIIa inhibitor derived from the hematophagous insect Triatoma infestans (rHA-Infestin-4). Statistical comparisons between 2 groups were evaluated by the Student t test or Mann-Whitney U test. RESULTS: In SBI-induced mice, we found abnormal activation of the coagulation cascade (factor XIII activity) and increased inflammation (myeloperoxidase activity) close to where emboli lodge in the brain. rHA-Infestin-4 administration significantly reduced ischemic damage (53% to 85% reduction of infarct volume, p < 0.05) and pathological coagulation (35% to 39% reduction of factor XIII activity, p < 0.05) without increasing hemorrhagic frequency. Myeloperoxidase activity, when normalized to the infarct volume, did not significantly change with rHA-Infestin-4 treatment, suggesting that this treatment does not further decrease inflammation other than that resulting from the reduction in infarct volume. CONCLUSIONS: Focal intracerebral clotting and inflammatory activity are part of the pathophysiology underlying SBI. Inhibiting factor XIIa with rHA-Infestin-4 may present a safe and effective treatment to decrease the morbidity of SBI.
Authors: Matthias Nahrendorf; Kai Hu; Stefan Frantz; Farouc A Jaffer; Ching-Hsuan Tung; Karl-Heinz Hiller; Sabine Voll; Peter Nordbeck; David Sosnovik; Stefan Gattenlöhner; Mikhail Novikov; Gerhard Dickneite; Guy L Reed; Peter Jakob; Anthony Rosenzweig; Wolfgang R Bauer; Ralph Weissleder; Georg Ertl Journal: Circulation Date: 2006-02-27 Impact factor: 29.690
Authors: Ina Hagedorn; Stefan Schmidbauer; Irina Pleines; Christoph Kleinschnitz; Ulrich Kronthaler; Guido Stoll; Gerhard Dickneite; Bernhard Nieswandt Journal: Circulation Date: 2010-03-22 Impact factor: 29.690
Authors: Michael O Breckwoldt; John W Chen; Lars Stangenberg; Elena Aikawa; Elisenda Rodriguez; Shumei Qiu; Michael A Moskowitz; Ralph Weissleder Journal: Proc Natl Acad Sci U S A Date: 2008-11-14 Impact factor: 11.205
Authors: Matthias Nahrendorf; David Sosnovik; John W Chen; Peter Panizzi; Jose-Luiz Figueiredo; Elena Aikawa; Peter Libby; Filip K Swirski; Ralph Weissleder Journal: Circulation Date: 2008-02-11 Impact factor: 29.690
Authors: Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt Journal: J Exp Med Date: 2005-07-11 Impact factor: 14.307
Authors: Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani Journal: Blood Date: 2014-01-09 Impact factor: 22.113
Authors: Sarah Hopp; Christiane Albert-Weissenberger; Stine Mencl; Michael Bieber; Michael K Schuhmann; Christian Stetter; Bernhard Nieswandt; Peter M Schmidt; Camelia-Maria Monoranu; Irina Alafuzoff; Niklas Marklund; Marc W Nolte; Anna-Leena Sirén; Christoph Kleinschnitz Journal: Ann Neurol Date: 2016-04-28 Impact factor: 10.422
Authors: Jennifer Krupka; Frauke May; Thomas Weimer; Ingo Pragst; Christoph Kleinschnitz; Guido Stoll; Con Panousis; Gerhard Dickneite; Marc W Nolte Journal: PLoS One Date: 2016-01-27 Impact factor: 3.240
Authors: Kristina Johansson; Jan-Håkan Jansson; Lars Johansson; Ingemar Bylesjö; Torbjörn K Nilsson; Mats Eliasson; Stefan Söderberg; Marcus Lind Journal: Cerebrovasc Dis Extra Date: 2017-04-21